- 著者
 
          - 
             
             Yamashita Takeshi
             
             Ogawa Satoshi
             
             Aizawa Yoshifusa
             
             Atarashi Hirotsugu
             
             Inoue Hiroshi
             
             Ohe Tohru
             
             Okumura Ken
             
             Kato Takao
             
             Kamakura Shiro
             
             Kumagai Koichiro
             
             Kurachi Yoshihisa
             
             Kodama Itsuo
             
             Koretsune Yukihiro
             
             Saikawa Tetsunori
             
             Sakurai Masayuki
             
             Sugi Kaoru
             
             Nakaya Haruaki
             
             Nakayama Toshio
             
             Hirai Makoto
             
             Fukatani Masahiko
             
             Mitamura Hideo
             
             Yamazaki Tsutomu
             
          
 
          
          
          - 出版者
 
          - 社団法人日本循環器学会
 
          
          
          - 雑誌
 
          - Circulation journal : official journal of the Japanese Circulation Society (ISSN:13469843)
 
          
          
          - 巻号頁・発行日
 
          - vol.67, no.9, pp.738-741, 2003-08-20 
 
          
          
          
          - 被引用文献数
 
          - 
             
             22
             
             
             50
             
             
          
        
 
        
        
        The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM study) is a randomized comparative evaluation of rate control and rhythm control, both combined with antithrombotic therapy, as therapeutic strategies for the treatment of atrial fibrillation (AF). This study differs from the earlier AFFIRM and RACE studies in that it has a composite primary end-point representing mortality and also physical/psychological disablement (total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, hospitalization for heart failure requiring intravenous administration of diuretics, and patient disablement). Patients' will to change the therapeutic strategy to the other is also considered as an end-point representing disablement under the assigned strategy. The secondary end-point includes quality of life scores and the efficacy and safety of drugs used in treating AF. The J-RHYTHM study emphasizes patient-reported experience and perception of AF-specific disablement, and the safety of antiarrhythmics available in Japan; it will follow 2,600 patients treated at more than 150 sites in Japan for a 3-year period. (Circ J 2003; 67: 738-741)